ArticleBone reports2026

MRONJ risk associated with combined antiresorptive and vascular endothelial growth factor receptor tyrosine kinase inhibitors.

G Mammone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.